| Literature DB >> 27478403 |
Kyle J Sanniec1, Cristine S Velazco2, Lyndsey A Bryant3, Nan Zhang4, William J Casey3, Raman C Mahabir3, Alanna M Rebecca3.
Abstract
Background. Sarcoma is a rare malignancy, and more recent management algorithms emphasize a multidisciplinary approach and limb salvage, which has resulted in an increase in overall survival and limb preservation. However, limb salvage has resulted in a higher rate of wound complications. Objective. To compare the complications between immediate and delayed (>three weeks) reconstruction in the multidisciplinary limb salvage sarcoma patient population. Methods. A ten-year retrospective review of patients who underwent sarcoma resection was performed. The outcome of interest was wound complication in the postoperative period based on timing of reconstruction. We defined infection as any infection requiring intravenous antibiotics, partial flap failure as any flap requiring a debridement or revision, hematoma/seroma as any hematoma/seroma requiring drainage, and wound dehiscence as a wound that was not completely intact by three weeks postoperatively. Results. 70 (17 delayed, 53 immediate) patients who underwent sarcoma resection and reconstruction met the inclusion criteria. Delayed reconstruction significantly increased the incidence of postoperative wound infection and wound dehiscence. There was no difference in partial or total flap loss, hematoma, or seroma between the two groups. Discussion and Conclusion. Immediate reconstruction results in decreased wound complications may reduce the morbidity associated with multidisciplinary treatment in the limb salvage sarcoma patient.Entities:
Year: 2016 PMID: 27478403 PMCID: PMC4961807 DOI: 10.1155/2016/7972318
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Characteristics of the study population by reconstructive type.
| Delayed ( | Immediate ( | Total ( |
| |
|---|---|---|---|---|
|
| 0.3613 | |||
| Mean (SD) | 59.8 (16.9) | 64.3 (18.0) | 63.2 (17.8) | |
| Median (range) | 66.0 (17.0–81.0) | 67.0 (22.0–94.0) | 66.5 (17.0–94.0) | |
|
| ||||
|
| 11 (64.7%) | 33 (62.3%) | 44 (62.9%) | 1.0000 |
|
| ||||
|
| 0.4740 | |||
| Myxofibrosarcoma | 5 (29.4%) | 7 (13.2%) | 12 (17.1%) | |
| Synovial sarcoma | 1 (5.9%) | 5 (9.4%) | 6 (8.6%) | |
| Leiomyosarcoma | 2 (11.8%) | 4 (7.5%) | 6 (8.6%) | |
| Liposarcoma | 2 (11.8%) | 3 (5.7%) | 5 (7.1%) | |
| Sarcoma NOS | 2 (11.8%) | 4 (7.5%) | 6 (8.6%) | |
| Myxoid chondrosarcoma | 1 (5.9%) | 0 (0.0%) | 1 (1.4%) | |
| Myxoid liposarcoma | 2 (11.8%) | 2 (3.8%) | 4 (5.7%) | |
| Fibrous histiocytoma | 0 (0.0%) | 5 (9.4%) | 5 (7.1%) | |
| Fibrosarcoma | 0 (0.0%) | 4 (7.5%) | 4 (5.7%) | |
| Pleomorphic sarcoma | 0 (0.0%) | 7 (13.2%) | 7 (10.0%) | |
| Spindle cell sarcoma | 1 (5.9%) | 3 (5.7%) | 4 (5.7%) | |
| Pleomorphic liposarcoma | 1 (5.9%) | 0 (0.0%) | 1 (1.4%) | |
| Dermatofibrosarcoma protuberans | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Angiosarcoma, high grade | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Giant cell rich extraosseous osteosarcoma | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Fibroblastic sarcoma | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Epithelioid angiosarcoma | 0 (0.0%) | 2 (3.8%) | 2 (2.9%) | |
| Osteosarcoma | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Neurofibrosarcoma | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
| Epitheloid sarcoma | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | |
|
| ||||
|
| 8 (47.1%) | 14 (26.4%) | 22 (31.4%) | 0.1381 |
|
| ||||
|
| 14 (82.4%) | 34 (64.2%) | 48 (68.6%) | 0.2324 |
|
| ||||
|
| 0.1167 | |||
| Mean (SD) | 39.9 (19.7) | 30.0 (23.3) | 32.4 (22.7) | |
| Median | 50.0 (0.0–50.4) | 45.0 (0.0–50.4) | 50.0 (0.0–50.4) | |
|
| ||||
|
| 9 (52.9%) | 16 (30.2%) | 25 (35.7%) | 0.1443 |
|
| ||||
|
| 0.1240 | |||
| Mean (SD) | 6.8 (6.7) | 4.0 (6.2) | 4.7 (6.4) | |
| Median (Range) | 10.0 (0.0–15.0) | 0.0 (0.0–17.5) | 0.0 (0.0–17.5) | |
|
| ||||
|
| 8 (47.1%) | 7 (13.2%) | 15 (21.4%) | 0.0060 |
|
| ||||
|
| 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | 1.0000 |
|
| ||||
|
| 1 (5.9%) | 5 (9.4%) | 6 (8.6%) | 1.0000 |
|
| ||||
|
| 4 (23.5%) | 4 (7.5%) | 8 (11.4%) | 0.0911 |
|
| ||||
|
| 1 (5.9%) | 5 (9.4%) | 6 (8.6%) | 1.0000 |
|
| ||||
|
| 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | 1.0000 |
1Fisher's exact test was used for categorical variables and two sample t-test was used for continuous variables. (p < 0.05 significant). gy = gray.
Flap type.
| Type of flap | Delayed ( | Immediate ( | Total ( |
|---|---|---|---|
| Free TRAM | 4 (23.5%) | 3 (5.7%) | 7 (10.0%) |
| Pedicle TRAM | 3 (17.6%) | 4 (7.5%) | 7 (10.0%) |
| Free VRAM | 1 (5.9%) | 0 (0.0%) | 1 (1.4%) |
| Pedicle VRAM | 1 (5.9%) | 4 (7.5%) | 5 (7.1%) |
| Pedicle ALT | 3 (17.6%) | 0 (0.0%) | 3 (4.3%) |
| Free ALT | 0 (0.0%) | 3 (5.7%) | 3 (4.3%) |
| Pedicle rectus abdominis | 3 (17.6%) | 0 (0.0%) | 3 (4.3%) |
| Free rectus abdominis | 0 (0.0%) | 2 (3.8%) | 2 (2.9%) |
| Free gracilis | 1 (5.9%) | 0 (0.0%) | 1 (1.4%) |
| Pedicle gracilis | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Pedicle gastrocnemius | 1 (5.9%) | 5 (9.4%) | 6 (8.6%) |
| STSG | 0 (0.0%) | 5 (9.4%) | 5 (7.1%) |
| FTSG | 0 (0.0%) | 2 (3.8%) | 2 (2.9%) |
| Pectoralis major/latissimus dorsi | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| DIEP | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Free serratus anterior | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| TAP | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Free latissimus | 0 (0.0%) | 3 (5.7%) | 3 (4.3%) |
| Pedicle latissimus | 0 (0.0%) | 2 (3.8%) | 2 (2.9%) |
| Reverse radial forearm | 0 (0.0%) | 3 (5.7%) | 3 (4.3%) |
| Pedicle TFL | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Fasciocutaneous advancement | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Pedicle rectus femoris | 0 (0.0%) | 3 (5.7%) | 3 (4.3%) |
| Sural nerve graft | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Free fasciocutaneous | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Pedicle fasciocutaneous | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Local rotational | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
| Free lateral arm | 0 (0.0%) | 2 (3.8%) | 2 (2.9%) |
| Hemisoleus | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) |
TRAM = transverse rectus abdominis myocutaneous; VRAM = vertical rectus abdominis myocutaneous; STSG = split thickness skin graft; ALT = anterolateral thigh; FTSG = full thickness skin graft; RF = rectus femoris; TFL = tensor fascia lata; DIEP = deep inferior epigastric artery perforator.
Outcomes by reconstructive type (univariate).
| Outcome | Delayed ( | Immediate ( |
|
|---|---|---|---|
| Infection requiring IV antibiotics | 8 (47.1%) | 5 (9.4%) | 0.0016 |
| Flap failure | 0 (0.0%) | 3 (5.7%) | 1.0000 |
| Partial flap loss | 4 (23.5%) | 5 (9.4%) | 0.2059 |
| Wound dehiscence/drainage | 11 (64.7%) | 16 (30.2%) | 0.0203 |
| Hematoma | 4 (23.5%) | 3 (5.7%) | 0.0542 |
| Seroma | 5 (29.4%) | 11 (20.8%) | 0.5133 |
1 p value is from Fisher's exact test.